Sinai in the past and, ironically, has an ongoing collaboration with a researcher there to develop a cell therapy for COVID-19. Except that there are several pharmaceutical companies and research labs well along the trial path for COVID-19 antibodies. Vaccinating everyone in the world against COVID-19 would require 7.8 billion doses, rolled out lickety-split. Washington has also secured virtually the entire world supply of remdesivir, an antiviral drug that shortens hospital stays for COVID-19 patients. “I believe the government thinks, well, AbCellera is going to be our antibody,” says Sidhu.

Source: thestar August 04, 2020 21:00 UTC